First-In-Human Study of Immbio’s Novel Pneumococcal Vaccine Pnubiovax Shows Vaccine to be Safe and Immunogenic

First-In-Human Study of Immbio’s Novel Pneumococcal Vaccine Pnubiovax Shows Vaccine to be Safe and Immunogenic
Data presented as invited oral presentation at 10th International Symposium on Pneumococci & Pneumococcal Diseases
 Antibody responses to ubiquitous antigens across strains shown, indicative of broad protection
 Statistically significant increases in antibody response were achieved in the 200 (mid) and 500 μg (high) dose groups, in comparison to the placebo group
 100% of subjects in the high dose group achieved a significant immune response
 Study demonstrated a dose response relationship
 Proven safety will allow further development of the vaccine, specific to at-risk groups for pneumococcal disease